Please disable your adblock and script blockers to view this page

COVID-19: Vaccine may be ready by fall and other reasons for hope

Medical News Today
the World Health Organization (WHO
the University of Alberta
Cornell University
Oxford University’s
Jenner Institute
the University of Reading
the University of Lincoln
the Chimp Adenovirus
COVID-19-induced ARDS
Deaconess Medical Center
Nuffield Department of Medicine
John Radcliffe Hospital

Matthias Götte
Susan Daniel
Susan DanielSarah Gilbert
Ian Jones
U.K.Colin Butter
David Salisbury
Ian Jones Tissue
Michael B. Yaffe
Christopher D. Barrett
David Bonsall


No matching tags

No matching tags

the United Kingdom

No matching tags

Positivity     39.31%   
   Negativity   60.69%
The New York Times
Write a review:

Two recent MNT articles COVID-19: 5 reasons to be cautiously hopeful and COVID-19: Physical distancing, drug trials offer hope looked at the latest developments in potential treatments, vaccines, and the outcomes of infection control measures during the pandemic.We continue our series with this third Special Feature, which continues to monitor progress in the areas mentioned above.Stay informed with live updates on the current COVID-19 outbreak and visit our coronavirus hub for more advice on prevention and treatment.We focus on a vaccine that some researchers believe may be available by the fall and round up expert opinions on this promising development. “What’s really interesting about SARS-CoV and MERS-CoV, and this new virus, SARS-CoV-2, is this particular part of the protein, the fusion peptide, is almost exactly the same in those three viruses,” explains study co-author Prof. The approach “uses a harmless chimpanzee virus to carry the fragment of SARS-CoV-2 that is required for immunity,” explains Ian Jones, Professor of virology at the University of Reading, U.K.Colin Butter, an associate professor of bioveterinary science at the University of Lincoln in the UK, explains: “Professor Gilbert’s team […] have made a recombinant vaccine against the SARS-CoV-2 virus by taking a virus that is entirely harmless to humans, the Chimp Adenovirus designated ChAdOx1, and inserting into it the spike protein gene from the [new] coronavirus.” Prof. “We suspect these patients with aggressive clotting will show the most benefit from tPA treatment, and this new clinical trial will reveal whether that’s the case,” says Dr. Yaffe.The scientists have started to recruit some of the COVID-19 patients admitted to the BIDMC for the trial. If app users decide to share additional data, they could support health services to identify trends and target interventions to reach those most in need.”The findings could pave the way for “intelligent [physical] distancing,” avoiding the social and economic effects of full lockdowns.For live updates on the latest developments regarding the novel coronavirus and COVID-19, click here.We take a look at some recent studies that help explain how SARS-CoV-2, the virus that causes COVID-19, is so effective at attacking human cells.From animal viruses fighting the human immune system, to possible COVID-19 scenarios, we explore the factors that shed light on a complex question.We look at what infectious disease experts have to say about when the pandemic will be over and how long it will take to develop and produce a vaccine.As the world faces a ventilator shortage, we examine the ethical implications of some of the hardest decisions to make during the COVID-19 pandemic.This live article covers developments regarding the coronavirus and COVID-19.

As said here by